...
首页> 外文期刊>International Journal of Molecular Sciences >Naltrexone Use in Treating Hypersexuality Induced by Dopamine Replacement Therapy: Impact of OPRM1 A/G Polymorphism on Its Effectiveness
【24h】

Naltrexone Use in Treating Hypersexuality Induced by Dopamine Replacement Therapy: Impact of OPRM1 A/G Polymorphism on Its Effectiveness

机译:Naltrexone用于治疗多巴胺替代疗法诱导的高缺血性:OPRM1 A / G多态性对其有效性的影响

获取原文
           

摘要

Hypersexuality is a well-known adverse side effect of dopamine replacement therapy (DRT), and anti-craving drugs could be an effective therapeutic option. Our aim was to update the knowledge on this issue, particularly on the influence of an Opioid Receptor Mu 1 ( OPRM1 ) genetic polymorphism. A systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. We also analyzed a case of iatrogenic hypersexuality that occurred in a patient treated with DRT. An analysis of the OPRM1 gene was performed on said patient. Our search identified 597 publications, of which only 7 were included in the final data synthesis. All seven publications involved naltrexone use. Five of them were case reports. None of the publications mentioned DRT side effects, nor did they report genetic data. Regarding our case report, the introduction of naltrexone corresponded with the resolution of the patient’s hypersexuality. Moreover, the patient carried the A/G genotype, which has been reported to be associated with a stronger response to naltrexone for patients with an alcohol use disorder. Although studies are inconclusive so far, naltrexone could be an interesting therapeutic option for resistant hypersexuality due to DRT. Carrying the A/G genotype could help explain a good response to treatment.
机译:HyperseXuality是多巴胺替代疗法(DRT)的众所周知的不利副作用,抗渴望药物可能是有效的治疗选择。我们的目标是更新关于该问题的知识,特别是对阿片类受体MU 1(OPRM1)遗传多态性的影响。根据首选报告项目进行系统审查,用于系统评价和荟萃分析(PRISMA)声明。我们还分析了在用DRT治疗的患者中发生的患者发生的案例。对所述患者进行对OPRM1基因的分析。我们的搜索已确定597个出版物,其中仅包含7个已包含在最终数据综合中。所有七种出版物都涉及NALTrexone使用。其中五个是案例报告。没有出版物提到DRT副作用,也没有报告遗传数据。关于我们的案例报告,引入NALTrexone与患者的过度透明度的解决方案相对应。此外,患者携带A / G基因型,据报道,对于含酒精障碍的患者对纳曲酮的反应较强。虽然到目前为止,研究尚无定论,但纳曲酮可能是由于DRT而导致的抗性过度性的有趣治疗选择。携带A / G基因型可以帮助解释对治疗的良好反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号